Altimmune, Inc. (NASDAQ:ALT) Receives $19.00 Consensus Price Target from Brokerages

Shares of Altimmune, Inc. (NASDAQ:ALT) have been given an average recommendation of “Buy” by the six research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $19.00.

A number of research firms have weighed in on ALT. HC Wainwright reissued a “buy” rating and issued a $12.00 target price on shares of Altimmune in a report on Friday, June 27th. Wall Street Zen downgraded Altimmune from a “hold” rating to a “sell” rating in a research note on Saturday, June 14th. Finally, William Blair reissued a “market perform” rating on shares of Altimmune in a research note on Friday, June 27th.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Ameriprise Financial Inc. boosted its position in shares of Altimmune by 35.6% during the fourth quarter. Ameriprise Financial Inc. now owns 5,254,898 shares of the company’s stock valued at $37,888,000 after buying an additional 1,378,854 shares during the period. Bellevue Group AG lifted its stake in shares of Altimmune by 9.5% during the 4th quarter. Bellevue Group AG now owns 945,446 shares of the company’s stock worth $6,817,000 after acquiring an additional 81,786 shares during the last quarter. Northern Trust Corp boosted its holdings in Altimmune by 5.7% during the 4th quarter. Northern Trust Corp now owns 665,916 shares of the company’s stock valued at $4,801,000 after acquiring an additional 35,918 shares during the period. Two Sigma Investments LP boosted its holdings in Altimmune by 33.2% during the 4th quarter. Two Sigma Investments LP now owns 605,303 shares of the company’s stock valued at $4,364,000 after acquiring an additional 151,001 shares during the period. Finally, Ensign Peak Advisors Inc grew its position in Altimmune by 39.2% in the 4th quarter. Ensign Peak Advisors Inc now owns 454,981 shares of the company’s stock valued at $3,280,000 after acquiring an additional 128,204 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Altimmune Trading Down 2.9%

Shares of NASDAQ:ALT opened at $4.76 on Tuesday. The stock has a market capitalization of $386.08 million, a price-to-earnings ratio of -3.78 and a beta of 0.47. The stock has a fifty day simple moving average of $5.71 and a two-hundred day simple moving average of $5.99. Altimmune has a 12-month low of $2.90 and a 12-month high of $11.16.

Altimmune (NASDAQ:ALT) last posted its earnings results on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.09. The business had revenue of $0.01 million during the quarter, compared to analyst estimates of $0.00 million. Altimmune had a negative return on equity of 65.44% and a negative net margin of 451,200.00%. During the same quarter last year, the company earned ($0.34) EPS. As a group, equities research analysts predict that Altimmune will post -1.35 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.